ACTG--ATOVAQUONE /AZITHROMYCIN COMPARED TO TRIMETHOPRIM-SULFAMETHOXAZOLE

ACTG--阿托伐醌/阿奇霉素与甲氧苄啶-磺胺甲恶唑相比

• 批准号: 6245189
• 负责人: Ram Yogev
• 金额: $ 1.2万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-15 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245189
• 关键词: AIDS therapy; atovaquone; azithromycin; clinical research; clinical trials; combination chemotherapy; disease /disorder prevention /control; drug interactions; drug screening /evaluation; drug tolerance; human subject; human therapy evaluation; longitudinal human study; opportunistic infections; outcomes research; pharmacokinetics; secondary infection; sulfamethoxazole; trimethoprim

The purpose of this study is to determine the comparability of Azithromycin plus m-Atovaquone to TMP/SMX in the prevention of serious bacterial infections; to determine and compare the long-term safety and tolerance of TMP/SMX vs. m-Atovaquone/Azithromycin; and to look at the likelihood of a pharmacokinetic interaction between m-Atovaquone and Azithromycin. Targeted accrual for this study is a total of 690 patients nationwide, with 340 patients on each treatment regime.

本研究的目的是确定以下内容的可比性 阿奇霉素加 m-Atovaquone 联合 TMP/SMX 预防严重 细菌感染；确定并比较长期安全性和 TMP/SMX 与 m-Atovaquone/阿奇霉素的耐受性；并看看 间阿托伐醌和间阿托伐醌之间药代动力学相互作用的可能性 阿奇霉素。 本研究的目标受试者总数为 690 名患者 在全国范围内，每种治疗方案有 340 名患者。